Clarification of dalfampridine labeled indications.

摘要

We are writing to correct an inaccuracy concerning the recommendations for use of dalfampridine that appeared in a paper by Miller et al., entitled "Approaches to the Management of Agents Used for the Treatment of Multiple Sclerosis: Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians," which appeared in the January/February 2012 issue of JMCP.